Click on the following links to see a summary of the trades made in 2009.
HGSI July 2009 trade
ACAD September 2009 trade
ACAD November 2009 trade
- Don't forget to Like our Sell The Call Facebook Page and follow our Sell The Call Twitter page!
- This information is not to be used as a recommendation to buy or sell. It is simply information and opinions. Before investing, please consult a financial professional. This blog takes no responsibility for any losses or gains that occur from trades using its material.
- The account does not fully divulge all information (the size of shares bought and calls sold) on open trades. This is for protection of the trade. When the trade on a particular stock ends, the account will give the size information out. Please feel free to ask questions and the account will answer them the best way possible can without endangering the trade. THE ACCOUNT WILL NOT MISLEAD READERS TO CREATE A GAIN ON ITS TRADES!
- If you have any info regarding call selling, be sure to comment or send an email. The goal of the blog is to collaborate so that we all can accumulate wealth with the help of selling calls. Please pass the blog address to others that might find some value from it.
Showing posts with label Acadia Pharmaceuticals. Show all posts
Showing posts with label Acadia Pharmaceuticals. Show all posts
Thursday, May 5, 2011
Monday, December 7, 2009
ACAD trade
Acadia Pharmaceuticals showed up on the account's Optionsxpress screener after the account finished its trade with Human Genome Services Inc. back in July of 2009. The company showed the very same traits as the HGSI trade. So the account ended up buying 100 shares at $2.34 and then selling the September 2009 $2.50 calls for $0.55. After commissions, the revenue from the call was $40.00.
At first the stock went all the way up past $5.00 per share. But then the news of a drug trial did not go well. This sent the shares down around $2.00. The call expired worthless.
There was a re-evaluation of the stock to see if the account should sell or hold on to the stock and sell another call. The decision was made to keep the stock and sell the November $2.50 call for revenue of $5.00. This brought total revenue of the trade to $45.00.
This did not go well. The stock fell all the way to $1.40 before the call expired. The account eventually sold the stock after the call expired.
The total loss on the trade including commissions of 37%.
Trading Notes on the trade will be coming soon.
At first the stock went all the way up past $5.00 per share. But then the news of a drug trial did not go well. This sent the shares down around $2.00. The call expired worthless.
There was a re-evaluation of the stock to see if the account should sell or hold on to the stock and sell another call. The decision was made to keep the stock and sell the November $2.50 call for revenue of $5.00. This brought total revenue of the trade to $45.00.
This did not go well. The stock fell all the way to $1.40 before the call expired. The account eventually sold the stock after the call expired.
The total loss on the trade including commissions of 37%.
Trading Notes on the trade will be coming soon.
Subscribe to:
Posts (Atom)
